513 related articles for article (PubMed ID: 28187915)
1. Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Thompson D; Richards D; Storey J; Dukes GE; Corrigan M; Oude Elferink RP; Beuers U; Hirschfield GM; Jones DE
Lancet; 2017 Mar; 389(10074):1114-1123. PubMed ID: 28187915
[TBL] [Abstract][Full Text] [Related]
2. BAT117213: Ileal bile acid transporter (IBAT) inhibition as a treatment for pruritus in primary biliary cirrhosis: study protocol for a randomised controlled trial.
Hegade VS; Kendrick SF; Dobbins RL; Miller SR; Richards D; Storey J; Dukes G; Gilchrist K; Vallow S; Alexander GJ; Corrigan M; Hirschfield GM; Jones DE
BMC Gastroenterol; 2016 Jul; 16(1):71. PubMed ID: 27431238
[TBL] [Abstract][Full Text] [Related]
3. Autotaxin, bile acid profile and effect of ileal bile acid transporter inhibition in primary biliary cholangitis patients with pruritus.
Hegade VS; Pechlivanis A; McDonald JAK; Rees D; Corrigan M; Hirschfield GM; Taylor-Robinson SD; Holmes E; Marchesi JR; Kendrick S; Jones DE
Liver Int; 2019 May; 39(5):967-975. PubMed ID: 30735608
[TBL] [Abstract][Full Text] [Related]
4. Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Evaluations Following Single Oral Doses of GSK2330672 in Healthy Japanese Volunteers.
Ino H; Endo A; Wakamatsu A; Ogura H; Numachi Y; Kendrick S
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):70-77. PubMed ID: 29870578
[TBL] [Abstract][Full Text] [Related]
5. GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus.
Levy C; Kendrick S; Bowlus CL; Tanaka A; Jones D; Kremer AE; Mayo MJ; Haque N; von Maltzahn R; Allinder M; Swift B; McLaughlin MM; Hirschfield GM;
Clin Gastroenterol Hepatol; 2023 Jul; 21(7):1902-1912.e13. PubMed ID: 36343847
[TBL] [Abstract][Full Text] [Related]
6. Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis.
Schramm C; Wedemeyer H; Mason A; Hirschfield GM; Levy C; Kowdley KV; Milkiewicz P; Janczewska E; Malova ES; Sanni J; Koo P; Chen J; Choudhury S; Klickstein LB; Badman MK; Jones D
JHEP Rep; 2022 Nov; 4(11):100544. PubMed ID: 36267872
[TBL] [Abstract][Full Text] [Related]
7. Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial.
de Vries E; Bolier R; Goet J; Parés A; Verbeek J; de Vree M; Drenth J; van Erpecum K; van Nieuwkerk K; van der Heide F; Mostafavi N; Helder J; Ponsioen C; Oude Elferink R; van Buuren H; Beuers U;
Gastroenterology; 2021 Feb; 160(3):734-743.e6. PubMed ID: 33031833
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of Elafibranor in Primary Biliary Cholangitis.
Kowdley KV; Bowlus CL; Levy C; Akarca US; Alvares-da-Silva MR; Andreone P; Arrese M; Corpechot C; Francque SM; Heneghan MA; Invernizzi P; Jones D; Kruger FC; Lawitz E; Mayo MJ; Shiffman ML; Swain MG; Valera JM; Vargas V; Vierling JM; Villamil A; Addy C; Dietrich J; Germain JM; Mazain S; Rafailovic D; Taddé B; Miller B; Shu J; Zein CO; Schattenberg JM; ;
N Engl J Med; 2024 Feb; 390(9):795-805. PubMed ID: 37962077
[TBL] [Abstract][Full Text] [Related]
10. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis.
Hirschfield GM; Bowlus CL; Mayo MJ; Kremer AE; Vierling JM; Kowdley KV; Levy C; Villamil A; Ladrón de Guevara Cetina AL; Janczewska E; Zigmond E; Jeong SH; Yilmaz Y; Kallis Y; Corpechot C; Buggisch P; Invernizzi P; Londoño Hurtado MC; Bergheanu S; Yang K; Choi YJ; Crittenden DB; McWherter CA;
N Engl J Med; 2024 Feb; 390(9):783-794. PubMed ID: 38381664
[TBL] [Abstract][Full Text] [Related]
11. Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial.
Bolier R; de Vries ES; Parés A; Helder J; Kemper EM; Zwinderman K; Elferink RPO; Beuers U;
Trials; 2017 May; 18(1):230. PubMed ID: 28535810
[TBL] [Abstract][Full Text] [Related]
12. A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA.
Schattenberg JM; Pares A; Kowdley KV; Heneghan MA; Caldwell S; Pratt D; Bonder A; Hirschfield GM; Levy C; Vierling J; Jones D; Tailleux A; Staels B; Megnien S; Hanf R; Magrez D; Birman P; Luketic V
J Hepatol; 2021 Jun; 74(6):1344-1354. PubMed ID: 33484775
[TBL] [Abstract][Full Text] [Related]
13. Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis.
Al-Dury S; Wahlström A; Wahlin S; Langedijk J; Elferink RO; Ståhlman M; Marschall HU
Sci Rep; 2018 Apr; 8(1):6658. PubMed ID: 29704003
[TBL] [Abstract][Full Text] [Related]
14. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
Jones D; Boudes PF; Swain MG; Bowlus CL; Galambos MR; Bacon BR; Doerffel Y; Gitlin N; Gordon SC; Odin JA; Sheridan D; Wörns MA; Clark V; Corless L; Hartmann H; Jonas ME; Kremer AE; Mells GF; Buggisch P; Freilich BL; Levy C; Vierling JM; Bernstein DE; Hartleb M; Janczewska E; Rochling F; Shah H; Shiffman ML; Smith JH; Choi YJ; Steinberg A; Varga M; Chera H; Martin R; McWherter CA; Hirschfield GM
Lancet Gastroenterol Hepatol; 2017 Oct; 2(10):716-726. PubMed ID: 28818518
[TBL] [Abstract][Full Text] [Related]
15. Glucose and lipid effects of the ileal apical sodium-dependent bile acid transporter inhibitor GSK2330672: double-blind randomized trials with type 2 diabetes subjects taking metformin.
Nunez DJ; Yao X; Lin J; Walker A; Zuo P; Webster L; Krug-Gourley S; Zamek-Gliszczynski MJ; Gillmor DS; Johnson SL
Diabetes Obes Metab; 2016 Jul; 18(7):654-62. PubMed ID: 26939572
[TBL] [Abstract][Full Text] [Related]
16. Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Miethke AG; Moukarzel A; Porta G; Covarrubias Esquer J; Czubkowski P; Ordonez F; Mosca A; Aqul AA; Squires RH; Sokal E; D'Agostino D; Baumann U; D'Antiga L; Kasi N; Laborde N; Arikan C; Lin CH; Gilmour S; Mittal N; Chiou FK; Horslen SP; Huber WD; Jaecklin T; Nunes T; Lascau A; Longpre L; Mogul DB; Garner W; Vig P; Hupertz VF; Gonzalez-Peralta RP; Ekong U; Hartley J; Laverdure N; Ovchinsky N; Thompson RJ
Lancet Gastroenterol Hepatol; 2024 May; ():. PubMed ID: 38723644
[TBL] [Abstract][Full Text] [Related]
17. Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis.
Kremer AE; Mayo MJ; Hirschfield G; Levy C; Bowlus CL; Jones DE; Steinberg A; McWherter CA; Choi YJ
Liver Int; 2022 Jan; 42(1):112-123. PubMed ID: 34403559
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of colesevelam for the treatment of bile acid diarrhoea: a double-blind, randomised, placebo-controlled, phase 4 clinical trial.
Borup C; Vinter-Jensen L; Jørgensen SPG; Wildt S; Graff J; Gregersen T; Zaremba A; Borup Andersen T; Nøjgaard C; Timm HB; Rainteau D; Hansen SH; Rumessen JJ; Munck LK
Lancet Gastroenterol Hepatol; 2023 Apr; 8(4):321-331. PubMed ID: 36758570
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial.
Ovchinsky N; Aumar M; Baker A; Baumann U; Bufler P; Cananzi M; Czubkowski P; Durmaz Ö; Fischer R; Indolfi G; Karnsakul WW; Lacaille F; Lee WS; Maggiore G; Rosenthal P; Ruiz M; Sokal E; Sturm E; van der Woerd W; Verkade HJ; Wehrman A; Clemson C; Yu Q; Ni Q; Ruvido J; Manganaro S; Mattsson JP
Lancet Gastroenterol Hepatol; 2024 Apr; ():. PubMed ID: 38670135
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study.
Gonzales E; Hardikar W; Stormon M; Baker A; Hierro L; Gliwicz D; Lacaille F; Lachaux A; Sturm E; Setchell KDR; Kennedy C; Dorenbaum A; Steinmetz J; Desai NK; Wardle AJ; Garner W; Vig P; Jaecklin T; Sokal EM; Jacquemin E
Lancet; 2021 Oct; 398(10311):1581-1592. PubMed ID: 34755627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
